Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
REGN 
Regeneron Pharmaceuticals Inc (REGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: REGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $768.36
1 Year Target Price $768.36
| 14 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.6% | Avg. Invested days 52 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 78.64B USD | Price to earnings Ratio 17.98 | 1Y Target Price 768.36 |
Price to earnings Ratio 17.98 | 1Y Target Price 768.36 | ||
Volume (30-day avg) 25 | Beta 0.39 | 52 Weeks Range 475.17 - 796.57 | Updated Date 12/3/2025 |
52 Weeks Range 475.17 - 796.57 | Updated Date 12/3/2025 | ||
Dividends yield (FY) 0.35% | Basic EPS (TTM) 41.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.13% | Operating Margin (TTM) 29.56% |
Management Effectiveness
Return on Assets (TTM) 6.16% | Return on Equity (TTM) 15.19% |
Valuation
Trailing PE 17.98 | Forward PE 17.83 | Enterprise Value 73098058940 | Price to Sales(TTM) 5.52 |
Enterprise Value 73098058940 | Price to Sales(TTM) 5.52 | ||
Enterprise Value to Revenue 5.13 | Enterprise Value to EBITDA 12.8 | Shares Outstanding 103282318 | Shares Floating 98557045 |
Shares Outstanding 103282318 | Shares Floating 98557045 | ||
Percent Insiders 2 | Percent Institutions 89.95 |
Upturn AI SWOT
Regeneron Pharmaceuticals Inc
Company Overview
History and Background
Regeneron Pharmaceuticals Inc. was founded in 1988 by Leonard S. Schleifer and George D. Yancopoulos. It initially focused on nerve growth factors and regeneration. A major milestone was the development of VelociSuite technologies, which accelerated antibody drug discovery.
Core Business Areas
- Eye Disease: Develops and commercializes therapies for serious eye diseases, including macular degeneration, diabetic macular edema, and retinal vein occlusion. EYLEA is a key product in this segment.
- Inflammatory Diseases: Focuses on therapies for inflammatory diseases such as atopic dermatitis (eczema) and asthma. DUPIXENT is a major product in this area.
- Oncology: Develops and commercializes therapies for various types of cancer, including Libtayo and research in bispecific antibodies.
- Cardiovascular Disease: Develops therapies for high cholesterol and cardiovascular disease.
Leadership and Structure
Leonard S. Schleifer is the co-founder, President, and CEO. George D. Yancopoulos is the co-founder, President, and Chief Scientific Officer. The company operates with a functional structure, with divisions focusing on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- EYLEA (aflibercept): A VEGF inhibitor used to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal diseases. Competitors include Novartis's Beovu and Roche's Lucentis and Vabysmo. EYLEA's global net product sales were approximately $5.8 billion in 2023. Market share varies by region but is significant in the anti-VEGF market.
- DUPIXENT (dupilumab): A monoclonal antibody used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Marketed in collaboration with Sanofi. Competitors include AbbVie's Rinvoq and Pfizer's Cibinqo for atopic dermatitis. DUPIXENT's global sales were approximately $11.6 billion in 2023.
- Libtayo (cemiplimab): An anti-PD-1 therapy used to treat certain types of cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Competitors include Merck's Keytruda and Bristol Myers Squibb's Opdivo. Libtayo global sales reached $822 million in 2023.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, long development timelines, stringent regulatory requirements, and intense competition. Biologics and specialty drugs are increasingly important.
Positioning
Regeneron is positioned as an innovative biopharmaceutical company with a strong focus on scientific discovery and drug development. Its VelociSuite technologies give it a competitive advantage in antibody discovery.
Total Addressable Market (TAM)
The total addressable market for Regeneron's therapeutic areas exceeds hundreds of billions of dollars. Regeneron is well-positioned to capture a significant share through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Proprietary VelociSuite technologies
- Successful commercial products (EYLEA, DUPIXENT, Libtayo)
- Strategic collaborations (e.g., with Sanofi)
- Experienced management team
Weaknesses
- Reliance on a few key products
- Exposure to patent expirations
- High R&D expenses
- Competition from larger pharmaceutical companies
Opportunities
- Expanding indications for existing products
- Developing new therapies for unmet medical needs
- Strategic acquisitions and partnerships
- Growth in emerging markets
Threats
- Competition from biosimilars and generics
- Regulatory challenges and pricing pressures
- Clinical trial failures
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- ABBV
- NVS
- LLY
- PFE
- BMY
- AMGN
Competitive Landscape
Regeneron competes with larger pharmaceutical companies across its therapeutic areas. Its strengths lie in its innovative research and development capabilities, while its weaknesses include reliance on a few key products.
Major Acquisitions
Decibel Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 109
- Strategic Rationale: Expand Regeneron's gene therapy capabilities for hearing disorders.
Growth Trajectory and Initiatives
Historical Growth: Regeneron has experienced significant revenue growth over the past decade, driven by the successful commercialization of EYLEA and DUPIXENT.
Future Projections: Analysts project continued revenue growth for Regeneron, driven by expanding indications for existing products and the launch of new therapies.
Recent Initiatives: Recent initiatives include expanding the indications for DUPIXENT and Libtayo, advancing its pipeline of bispecific antibodies, and investing in new research technologies.
Summary
Regeneron is a strong biopharmaceutical company with innovative research capabilities and successful commercial products. EYLEA and DUPIXENT are key growth drivers, and the company has a robust pipeline of new therapies. However, Regeneron faces competition from larger pharmaceutical companies and needs to diversify its product portfolio to mitigate risks associated with patent expirations.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Regeneron Pharmaceuticals Inc. Annual Reports, SEC Filings, Analyst Reports, Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered as financial advice. Market share data is approximate and may vary based on source and methodology. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regeneron Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Tarrytown, NY, United States | ||
IPO Launch date 1991-04-02 | Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15222 | Website https://www.regeneron.com |
Full time employees 15222 | Website https://www.regeneron.com | ||
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.